Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54.7M
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
15.9M
-
Shares change
-
+1.7M
-
Total reported value, excl. options
-
$339M
-
Value change
-
+$30.1M
-
Number of buys
-
36
-
Number of sells
-
-28
-
Price
-
$21.49
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q3 2019
71 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2019.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.9M shares
of 54.7M outstanding shares and own 29.13% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (3.36M shares), GILDER GAGNON HOWE & CO LLC (1.88M shares), Cormorant Asset Management, LP (1.79M shares), JANUS HENDERSON GROUP PLC (1.14M shares), RA CAPITAL MANAGEMENT, L.P. (1.12M shares), Redmile Group, LLC (1.02M shares), MILLENNIUM MANAGEMENT LLC (698K shares), VANGUARD GROUP INC (674K shares), PERCEPTIVE ADVISORS LLC (672K shares), and BlackRock Inc. (619K shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.